Roupen Odabashian: The ability to measure a marker doesn’t equate to clinical benefit

Roupen Odabashian posted on LinkedIn:

“The ability to measure a marker doesn’t equate to clinical benefit.

I have seen many startups capable of measuring specific markers and hypothesizing potential outcomes from measuring these markers.

However, real-life applications often differ significantly.
This disconnect is particularly evident when tech founders from lab or academic backgrounds develop tests for various markers without early collaboration with physicians.

Even if a marker is mentioned in clinical guidelines, it doesn’t guarantee its practical use in medical decision-making.
To founders with academic or PhD backgrounds skilled in test development: I strongly advise early collaboration with physicians.

Don’t rely solely on guidelines.

Investigate whether measuring your marker can truly impact patient health or medical practice.

This approach can bridge the gap between theoretical potential and real-world clinical value.”

Source: Roupen Odabashian/LinkedIn

Dr. Roupen Odabashian is an accomplished Internal Medicine Physician and Hematology/Oncology Fellow with a profound commitment to advancing healthcare through clinical practice, research, and technology. Currently based at the prestigious Karmanos Cancer Institute, Dr. Odabashian is actively involved in pioneering cancer treatments and conducting clinical research.

In addition to his clinical work, Dr. Odabashian is a multifaceted healthcare professional. He hosts podcast at OncoDaily, engaging with leading experts in oncology to share valuable insights with the medical community. Dr. Odabashian also contributes his expertise as an advisor at Spiraldot Health and Mesh AI, supporting innovative ventures in healthcare technology and collaborative scheduling to combat clinician burnout. With his diverse roles and unwavering dedication, Dr. Odabashian exemplifies a commitment to driving positive change in healthcare.